CSLCSLLY -0.07%73 Debt-to-EBITDA is 5.24 as of Dec. 2025, which is 165% above its 10-year median of 1.98. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.68 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 292 Biotechnology companies, CSL ranks worse than 88.7% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for CSL's Debt-to-EBITDA or its related term are showing as below:
CSLLY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.6 Med: 1.98 Max: 10.49
Current: 10.49
During the past 13 years, the highest Debt-to-EBITDA Ratio of CSL was 10.49. The lowest was 1.60. And the median was 1.98.
CSLLY's Debt-to-EBITDA is ranked worse than 88.7% of 292
companies
in the Biotechnology industry
Industry Median: 1.205
vs CSLLY: 10.49
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CSL Debt-to-EBITDA Related Terms
CSL Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for CSL's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, CSL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CSL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
CSL (CSLLY) has a Debt-to-EBITDA of 5.24 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CSL. This is 165% above median its historical median of 1.98. Over the past decade, CSL's Debt-to-EBITDA has ranged from 1.60 to 10.49. According to the industry distribution chart, CSL ranks #259 out of 292 companies in the Biotechnology industry, placing it in the top 88.7%.
Is CSL's Debt-to-EBITDA too high?
CSL's current Debt-to-EBITDA of 5.24 is 165% above median its 10-year median of 1.98. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 10.49. The Biotechnology industry median Debt-to-EBITDA is 1.21. CSL's value of 5.24 is 334.9% above this industry median. Based on the distribution chart, CSL ranks #259 out of 292 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #259 out of 292 companies for Debt-to-EBITDA. This places CSL in the lower half of its industry. The industry median Debt-to-EBITDA is 1.21. CSL's value of 5.24 is 334.9% above this benchmark. Historically, CSL's own Debt-to-EBITDA has ranged from 1.60 to 10.49 over the past decade. While the company's 10-year median is 1.98 vs. the industry median of 1.21, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.21, based on 292 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Debt-to-EBITDA of 5.24 is 334.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CSL. For the Biotechnology industry, the median Debt-to-EBITDA is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Debt-to-EBITDA is 5.24, which is 165% above median its own 10-year median of 1.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.68, compared to a current price of $20.49 — trading 59.6% below its estimated fair value. The current Debt-to-EBITDA is 5.24, which is 165% above median its 10-year median of 1.98 and 334.9% above the Biotechnology industry median of 1.21. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CSL (CSLLY), the current Debt-to-EBITDA is 5.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $20.49 is trading 59.6% below its estimated GF Value™ of $50.68.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Debt-to-EBITDA: 5.24 (165% above median its 10-year median of 1.98)
GF Value™: $50.68 vs. price of $20.49 (59.6% below fair value)
Industry Position: 334.9% above the Biotechnology median (#259 of 292)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
